ReviewCurrent HIV/AIDS reports2010
New antituberculous drugs in development.
Review in Current HIV/AIDS reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Nanotechnology-Based Approach in Tuberculosis Treatment.Tuberculosis research and treatment · 2017Review
- Antitubercular therapy in patients with cirrhosis: challenges and options.World journal of gastroenterology · 2014Review
- Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15.Journal of natural products · 2013Article
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Future microbiology · 2012Review
- Pediatric drug-resistant tuberculosis: a global perspective: a global perspective.Paediatric drugs · 2011Review
- Monoenomycin: A Simplified Trienomycin A Analogue that Manifests Anticancer Activity.ACS medicinal chemistry letters · 2011Article
- Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Expert opinion on drug safety · 2011Review
- Nanomedicine as an emerging approach against intracellular pathogens.International journal of nanomedicine · 2011Review
- Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There have been no new antituberculous drugs since the introduction of rifampin in 1952. The collision of the HIV and tuberculosis (TB) epidemics in developing regions of the world together with the emergence of multidrug resistance and extensively drug-resistant strains of TB has emphasized the urgent need for newer antituberculous drugs. There is a need for drugs that are safe, effective against resistant strains, are able to shorten the course of treatment, are effective for latent TB infection, and that have minimal interactions with antiretroviral drugs. Drugs that are currently in phase 3 development are moxifloxacin and gatifloxacin. In phase 2 development are PA-824 and TMC207; and in phase 1 are SQ109, AZD5847, and linezolid. Nanotechnology holds future promise for targeted drug delivery. Immunotherapy such as new vaccines and vitamin D may serve as adjunctive treatment for prevention and active disease, together with shortening the course of treatment. Bringing newer and more effective antituberculous drugs to market is a global priority and the process must be accelerated.
Indexed as
Identifiers
20559756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.